DEF 14A: Health Catalyst Announces Details for 2024 Annual Stockholders Meeting

Health Catalyst's proxy statement details the agenda for the 2024 Annual Meeting of Stockholders, including director elections, auditor ratification, and executive compensation approval.

Summary

• Health Catalyst has released its proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024.
• Stockholders will vote on the election of three Class II directors: Daniel Burton, John A. Kane, and Julie Larson-Green.
• The meeting will also include a vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• An advisory, non-binding vote to approve the compensation of the company's named executive officers is also on the agenda.
• The board of directors recommends voting FOR the election of the director nominees, FOR the ratification of Ernst & Young LLP, and FOR the approval of the executive compensation.
• The record date for determining stockholders eligible to vote at the Annual Meeting was April 19, 2024.
• The meeting will be held virtually via a live interactive audio webcast.
• The proxy statement provides details on corporate governance, executive compensation, related party transactions, and other relevant information for stockholders.

Sentiment

Score: 6

Explanation: The document is neutral. While it highlights positive aspects like the board's recommendations and commitment to corporate social responsibility, it also acknowledges challenges such as the GAAP net loss and below-target growth metrics.

Positives

• The board recommends voting FOR all proposals.
• The company is committed to corporate social responsibility and ethical business practices.
• The company has a clawback policy in place to recover erroneously awarded compensation.
• The company has a stock ownership policy for executive officers and non-employee directors to align their interests with those of stockholders.
• The company achieved positive full-year Adjusted EBITDA in fiscal 2023 for the first time.

Negatives

• The company reported a GAAP net loss of $118.1 million for fiscal year 2023.
• The company's growth metrics were below target in fiscal year 2023 due to macroeconomic challenges and financial strain on the health system end market.
• The company's client satisfaction score in fiscal 2023 was 4.1, which met the minimum threshold of 4.1 but was below the performance target amount of 4.3.
• The company's Dollar-based Retention was below the minimum threshold of 106% in fiscal 2023.
• The company's ARR and NRR Gross Bookings was below the minimum threshold of $75 million in fiscal 2023.

Risks

• The company faces strategic, financial, business and operational, cybersecurity, legal and regulatory compliance, and reputational risks.
• The company's operating margins in the health system end market continue to be challenged due to increases in labor and supply costs.
• The company's future financial performance is subject to various risks and uncertainties.
• The company's ability to achieve its long-term strategic goals is subject to various risks and uncertainties.

Future Outlook

The company is focused on corporate social responsibility and ethical business practices. The company is focused on long-term growth and profitability.

Management Comments

• Daniel Burton, Chief Executive Officer and Director: 'Thank you for your ongoing support of and continued interest in Health Catalyst.'

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but it does mention that the operating margins of health systems continue to be challenged relative to longer-term historical levels, primarily due to significant increases in labor and supply costs without a commensurate increase in revenue.

Comparison to Industry Standards

• The document does not provide a detailed assessment of the results in the context of global benchmarks or specific comparable companies and projects.
• The document does not provide a detailed assessment of the results in the context of global benchmarks or specific comparable companies and projects.

Management Changes

Corporate Governance

Related Party Transactions

• Jeffrey Selander, the brother-in-law of Daniel Burton, is a non-executive employee, currently serving as Senior Vice President, and has served with us since September 2011.
• Matthew Kolb, a member of our board of directors since July 2023, serves as the Executive Vice President and Chief Operating Officer of Carle Health, a non-profit hospital network. We maintain on-going technology and professional service relationships with Carle Health, including technology access and professional services that includes Tech-enabled Managed Services (i.e., TEMS). We recognized revenue under these related party contracts of $8.1 million after the related party relationship commenced during the fiscal year ended December 31, 2023.

Stakeholder Impact

• The election of directors will impact the leadership and oversight of the company.
• The advisory vote on executive compensation allows stockholders to express their views on the company's pay practices.
• The company's financial performance and strategic decisions will affect stockholders, employees, customers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote their shares at the Annual Meeting.
• The board and management will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The company will continue to monitor and adapt to industry trends and challenges.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, Ernst & Young, stockholders, corporate governance, Health Catalyst